Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response

被引：0
|
作者：
Yosuke Sato
Yu Fu
Hong Liu
Min Young Lee
Michael H. Shaw
机构：
[1] Immuno-oncology Drug Discovery Unit,
[2] Millennium Pharmaceuticals,undefined
[3] Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited,undefined
[4] Guardant Health,undefined
[5] Checkmate Pharmaceuticals,undefined
来源：
BMC Cancer | / 21卷
关键词：
Immune checkpoint blockade; Anti-PD-1; Syngeneic model; CT-26; Colon 26; Anti-tumor activity; Wnt;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
    Sato, Yosuke
    Fu, Yu
    Liu, Hong
    Lee, Min Young
    Shaw, Michael H.
    BMC CANCER, 2021, 21 (01)
  • [2] Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments
    Zabransky, Daniel J.
    Danilova, Ludmila
    Leatherman, James M.
    Lopez-Vidal, Tamara Y.
    Sanchez, Jessica
    Charmsaz, Soren
    Gross, Nicole E.
    Shin, Sarah
    Yuan, Xuan
    Hernandez, Alexei
    Yang, Hongqui
    Xavier, Stephanie
    Shu, Daniel
    Saeed, Ali
    Munjal, Kabeer
    Kamdar, Zeal
    Kagohara, Luciane T.
    Jaffee, Elizabeth M.
    Yarchoan, Mark
    Ho, Won Jin
    HEPATOLOGY, 2023, 77 (05) : 1566 - 1579
  • [3] Molecular characterization of mouse syngeneic tumor models in response to treatment with anti-PD-1 immunotherapy
    Hirsch, Heather A.
    Pinheiro, Elaine M.
    Cai, Mingmei
    Ma, Yanhong
    Sathe, Manjiri
    Ayers, Mark
    McClanahan, Terrill K.
    CANCER RESEARCH, 2015, 75
  • [4] Anti-tumor activity of a TAM kinase-targeting compound in CT-26 syngeneic mouse model
    Lai, Shenshen
    Zhang, Hong
    Yan, Jun
    Zhang, Zaihui
    CANCER RESEARCH, 2017, 77
  • [5] Effects of treatment regimens on antitumor activity of lenvatinib and anti-PD-1 antibody combinations in the CT26 mouse colon cancer syngeneic model
    Kato, Y.
    Kimura, T.
    Tabata, K.
    Hori, Y.
    Yamada, K.
    Uehara, T.
    Ito, J.
    Ozawa, Y.
    Ichikawa, K.
    Matsui, J.
    Funahashi, Y.
    Nomoto, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E138 - E139
  • [6] Reduction of tumor hypoxia during anti-PD-1 therapy in a CT26 colon cancer model
    Nakajima, Kohei
    Suzuki, Motofumi
    Takakura, Hideo
    Kuge, Yuji
    Ogawa, Mikako
    CANCER SCIENCE, 2023, 114 : 1181 - 1181
  • [7] PD-1 antibody treatment induces gut microbiota changes in CT-26 colon cancer syngeneic model
    Ding, Jian
    Mao, Binchen
    Shi, Qian
    CANCER RESEARCH, 2017, 77
  • [8] Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms
    Abbott, Charles
    Levy, Eric
    Pyke, Rachel
    McClory, Rena
    Jang, Sekwon
    Chen, Richard
    Boyle, Sean
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [9] Calenduloside E 6′-methyl ester induces apoptosis in CT-26 mouse colon carcinoma cells and inhibits tumor growth in a CT-26 xenograft animal model
    Lee, Bora
    Lee, Dae Young
    Yoo, Ki Hyun
    Baek, Nam In
    Park, Jong-Hwa
    Chung, In Sik
    ONCOLOGY LETTERS, 2012, 4 (01) : 22 - 28
  • [10] Diallyl trisulfide (DATS) inhibits mouse colon tumor in mouse CT-26 cells allograft model in vivo
    Wu, Ping-Ping
    Liu, Kuo-Ching
    Huang, Wen-Wen
    Chueh, Fu-Shin
    Ko, Yang-Ching
    Chiu, Tsan-Hung
    Lin, Jing-Pin
    Kuo, Jehn-Hwa
    Yang, Jai-Sing
    Chung, Jing-Gung
    PHYTOMEDICINE, 2011, 18 (8-9) : 672 - 676
12345